Axsome Therapeutics Reports Robust Q4 Revenue Growth, Updates CNS Pipeline
Axsome Therapeutics reported robust year-over-year revenue growth in Q4 2025, driven by increased net product sales. The earnings call highlighted progress in its late-stage central nervous system pipeline, including upcoming data readouts for its lead migraine and depression therapy candidates.
1. Q4 2025 Financial Performance
Axsome Therapeutics delivered robust year-over-year revenue growth in Q4 2025, driven by net product sales of its approved therapies. The company noted broader market adoption and increased prescribing in core therapeutic areas, contributing to its strongest quarterly top-line performance so far.
2. Pipeline Progress
Management highlighted advances in its late-stage CNS pipeline, including forthcoming data readouts for its lead oral migraine and depression candidates. Preparations for New Drug Application submissions and regulatory interactions were also discussed, outlining key milestones for 2026.